JP2016534717A5 - - Google Patents

Download PDF

Info

Publication number
JP2016534717A5
JP2016534717A5 JP2016524494A JP2016524494A JP2016534717A5 JP 2016534717 A5 JP2016534717 A5 JP 2016534717A5 JP 2016524494 A JP2016524494 A JP 2016524494A JP 2016524494 A JP2016524494 A JP 2016524494A JP 2016534717 A5 JP2016534717 A5 JP 2016534717A5
Authority
JP
Japan
Prior art keywords
seq
cancer
chimeric receptor
cell
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016524494A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016534717A (ja
JP6417413B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/060999 external-priority patent/WO2015058018A1/en
Publication of JP2016534717A publication Critical patent/JP2016534717A/ja
Publication of JP2016534717A5 publication Critical patent/JP2016534717A5/ja
Application granted granted Critical
Publication of JP6417413B2 publication Critical patent/JP6417413B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016524494A 2013-10-17 2014-10-17 多様な腫瘍に対する抗体依存性細胞毒性を誘発するキメラ受容体 Active JP6417413B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361892218P 2013-10-17 2013-10-17
US61/892,218 2013-10-17
US201462026243P 2014-07-18 2014-07-18
US62/026,243 2014-07-18
PCT/US2014/060999 WO2015058018A1 (en) 2013-10-17 2014-10-17 Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors

Publications (3)

Publication Number Publication Date
JP2016534717A JP2016534717A (ja) 2016-11-10
JP2016534717A5 true JP2016534717A5 (https=) 2017-11-24
JP6417413B2 JP6417413B2 (ja) 2018-11-07

Family

ID=52828713

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016524494A Active JP6417413B2 (ja) 2013-10-17 2014-10-17 多様な腫瘍に対する抗体依存性細胞毒性を誘発するキメラ受容体

Country Status (11)

Country Link
EP (1) EP3057986B1 (https=)
JP (1) JP6417413B2 (https=)
KR (1) KR102308597B1 (https=)
CN (1) CN105683214B (https=)
AU (1) AU2014337195B2 (https=)
BR (1) BR112016007695A2 (https=)
CA (1) CA2926267C (https=)
IL (1) IL245088A0 (https=)
SG (1) SG11201602979RA (https=)
WO (1) WO2015058018A1 (https=)
ZA (1) ZA201602798B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2948544A4 (en) 2013-01-28 2016-08-03 St Jude Childrens Res Hospital CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
US10144770B2 (en) 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
DK3143134T3 (da) 2014-05-15 2021-01-04 Nat Univ Singapore Modificerede, naturlige dræberceller og anvendelser deraf
CA2972714A1 (en) * 2014-09-09 2016-03-17 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy
EP3711488A1 (en) 2015-05-06 2020-09-23 Snipr Technologies Limited Altering microbial populations & modifying microbiota
EP4289944A3 (en) * 2015-10-08 2024-03-13 National University Corporation Tokai National Higher Education and Research System Method for preparing genetically-modified t cells which express chimeric antigen receptor
EA201890960A1 (ru) * 2015-10-15 2018-10-31 Селулэрити, Инк. Натуральные киллеры и клетки ilc3 и их применение
GB201602974D0 (en) * 2016-02-19 2016-04-06 Clube Jasper R Engineered cells & methods (1)
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
WO2018017649A1 (en) * 2016-07-19 2018-01-25 Unum Therapeutics Inc. Use of antibody-coupled t cell receptor (actr) with multiple anti-cancer antibodies in cancer treatment
EP3315511A1 (en) 2016-10-29 2018-05-02 Miltenyi Biotec GmbH Adapter chimeric antigen receptor expressing cells for targeting of multiple antigens
NZ752984A (en) 2016-11-22 2026-03-27 Nat Univ Singapore Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
BR112019019917A2 (pt) 2017-03-27 2020-04-22 Nat Univ Singapore receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
CA3056591A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
WO2019056174A1 (zh) * 2017-09-19 2019-03-28 中山大学 一种过表达cxcr5的间质干细胞及其制备方法和用途
IL276365B2 (en) 2018-02-01 2023-10-01 Nkmax Co Ltd A method for the production of natural killer cells and a preparation for cancer treatment
EP3749685A4 (en) 2018-02-09 2021-12-22 National University of Singapore ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
WO2019222642A1 (en) * 2018-05-18 2019-11-21 Senti Biosciences, Inc. Engineered immune cells and methods of use
US12269863B2 (en) * 2018-05-23 2025-04-08 Manysmart Therapeutics, Inc. Bispecific T cell engager and uses thereof
AU2019299439C1 (en) 2018-07-03 2025-06-26 Sotio Biotech, Inc. Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
JP7456638B2 (ja) 2018-08-14 2024-03-27 ソティオ，リミティド ライアビリティ カンパニー クレブス回路を調節するトランス代謝分子と組み合わせたキメラ抗原受容体ポリペプチド、及び、それらの治療的使用
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
EP3620464A1 (en) 2018-09-10 2020-03-11 Miltenyi Biotec GmbH Car cell having crosslinked disulfide bridge on antigen recognizing moiety
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
CA3120563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
WO2020201527A1 (en) 2019-04-04 2020-10-08 Umc Utrecht Holding B.V. Modified immune receptor constructs
WO2021047804A1 (en) 2019-09-11 2021-03-18 Miltenyi Biotec B.V. & Co. KG In vitro method for transduction of t cells in the presence of malignant cells
EP3875478A1 (en) 2020-03-05 2021-09-08 Canvax Biotech, S.L. Novel non-immunogenic chimeric antigen receptors and uses thereof
EP3878464A1 (en) 2020-03-09 2021-09-15 Miltenyi Biotec B.V. & Co. KG Use of a car cell having crosslinked disulfide bridge on antigen recognizing moiety for targeting cancer cells
CN113583139A (zh) * 2020-07-06 2021-11-02 上海鑫湾生物科技有限公司 一种嵌合受体及其应用
EP4313087A4 (en) * 2021-03-30 2025-03-19 The Regents of the University of California PROTECTION OF TRANSPLANTED CELLS VIA MODIFIED FC RECEPTORS
WO2023049933A1 (en) 2021-09-27 2023-03-30 Sotio Biotech Inc. Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
WO2024040208A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
WO2024040207A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
AU7477394A (en) 1993-07-30 1995-03-27 University Of Medicine And Dentistry Of New Jersey Efficient gene transfer into primary lymphocytes
ATE483472T1 (de) * 2002-05-30 2010-10-15 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US20110123440A1 (en) * 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
US20080003225A1 (en) * 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
CA2694055A1 (en) * 2007-08-01 2009-02-05 Glaxo Group Limited Novel antibodies
US8067339B2 (en) * 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
DE102009013748B4 (de) * 2009-03-17 2012-01-26 Paul-Ehrlich-Institut Bestimmung von Interaktionen konstanter Antikörperteile mit Fc-gamma Rezeptoren
CA2776143A1 (en) * 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
AU2011289426A1 (en) * 2010-08-10 2013-02-28 Amgen Inc. Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA2972714A1 (en) * 2014-09-09 2016-03-17 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy

Similar Documents

Publication Publication Date Title
JP2016534717A5 (https=)
AU2014337195B2 (en) Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
JP2017515506A5 (https=)
FI3909972T3 (fi) Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä
JP7382829B2 (ja) キメラ抗原受容体を発現するｔ細胞
HRP20240494T1 (hr) Kimerni antigenski receptori specifični za bcma i njihove upotrebe
JP2016520074A5 (https=)
RU2017130985A (ru) Фармацевтическая композиция и способ снижения ингибирующего эффекта pd-l1 на т-клетки человека
JP2018506981A5 (https=)
JP2017513478A5 (https=)
RU2016143155A (ru) Cd33-специфические химерные антигенные рецепторы для иммунотерапии рака
RU2017129455A (ru) Сконструированные иммунные клетки с нокаутом рецептора т-клеток, снабженные химерными антигенными рецепторами, связывающимися с cd123, для лечения рецедивирующего/устойчивого острого миелоидного лейкоза или новообразования из бластных плазмоцитоидных дендритных клеток
IL311608A (en) Preparations and methods for the selective elimination and replacement of hematopoietic stem cells
JP2017515464A5 (https=)
JP2018029594A5 (https=)
JP2023138960A (ja) キメラ抗原受容体を発現する免疫細胞
RU2017102769A (ru) EGFRvIII СПЕЦИФИЧЕСКИЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ ДЛЯ ИММУНОТЕРАПИИ РАКА
JP2014533928A5 (https=)
JP2020513754A5 (https=)
RU2016143381A (ru) Способ и композиции для клеточной иммунотерапии
JP2018518990A5 (https=)
JP2017537627A5 (https=)
JP2017537622A5 (https=)
JP2016514462A5 (https=)
JP2017518071A5 (https=)